Emory University Biomarin Pharmaceutical Inc Transaction History

Emory University

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $1.77 Million - $2.24 Million	-26,278 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $72,475 - $84,697	902 Added 3.55%	26,278 $2.25 Million
Q1 2019 May 09, 2019	BUY	$84.2 - $98.62 $90,430 - $105,917	1,074 Added 4.42%	25,376 $2.25 Million
Q4 2018 Feb 12, 2019	BUY	$80.14 - $106.07 $1.95 Million - $2.58 Million	24,302 New	24,302 $2.07 Million

621

181M

1.73M

1.73M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Emory University, based on Form 13F filings with the SEC.

Stay updated on Emory University with notifications on news.